Dr. Sauter on Off-The-Shelf Versus Autologous CAR T-Cell Products in Hematologic Malignancies

Video

Craig Sauter, MD, discusses the differences between off-the-shelf and autologous chimeric antigen receptor T-cell products in patients with hematologic malignancies.

Craig Sauter, MD, a hematologic oncologist and clinical director of the Adult Bone Marrow Transplant Service at Memorial Sloan Kettering Cancer Center, discusses the differences between off-the-shelf and autologous chimeric antigen receptor (CAR) T-cell products in patients with hematologic malignancies.

The primary advantage of off-the-shelf CAR T-cell therapy is that patients have the opportunity to access cellular therapy in real time, as compared with autologous products that need to be manufactured in the lab, Sauter says.

Having more immediate access to these products is especially important for patients with poor-risk, relapsed/refractory lymphoma. For these patients, time is a critical component of their care; this is especially true for patients who aren’t responding to therapy, which is the current indication for CAR-modified T cells, Sauter adds.

However, there is a possibility that the off-the-shelf CAR T-cell therapy products can be rejected by the host immune system. Approaches to circumnavigate that risk are currently at the forefront of investigation, Sauter concludes.

Recent Videos
Tami John, MD
Tami John, MD
Tami John, MD
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital
Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Laura Aguilar MD, PhD, the chief medical officer of Diakonos Oncology
Jamie Jacobs, PhD, the program director of the center for psychiatric oncology & behavioral sciences at Mass General Cancer Center
Related Content
© 2025 MJH Life Sciences

All rights reserved.